BioVersys AG | Finanzwire

BRIEF

published on 03/18/2026 at 07:05, 3 days 6 hours ago

BioVersys Unveils 2025 Achievements and Financial Performance

Financial Results Clinical Trials BioVersys Antibacterial Drugs IPO Funding
PRESS RELEASE

published on 03/18/2026 at 07:00, 3 days 6 hours ago

BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
BioVersys AG reports corporate highlights and financial results for the full year 2025, including significant progress in clinical and regulatory advancements of antibacterial products for MDR bacteria

Financial Results BioVersys AG Antibacterial Products Clinical Progress Regulatory Advancements
BRIEF

published on 03/16/2026 at 07:05, 5 days 6 hours ago

BioVersys Gets FDA Nod for BV100 Phase 3 Trial for Pneumonia

FDA Approval Phase 3 Trial BV100 BioVersys CRAB Infections
PRESS RELEASE

published on 03/16/2026 at 07:00, 5 days 6 hours ago

BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
BioVersys receives US FDA green light for BV100 HABP/VABP Phase 3 pivotal trial start to address CRABC infections in hospital-acquired bacterial pneumonia. A significant step in developing novel antibacterial products for MDR bacteria

Phase 3 BV100 BioVersys US FDA CRABC
BRIEF

published on 03/12/2026 at 07:05, 9 days 6 hours ago

BioVersys Initiates Phase 2b Trial for AlpE in Tuberculosis Treatment

Drug Resistance BioVersys Tuberculosis AlpE Clinical Trial UNITE4TB
PRESS RELEASE

published on 03/12/2026 at 07:00, 9 days 6 hours ago

BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
BioVersys announces the first patient dosed in a Phase 2b clinical trial of AlpE for pulmonary tuberculosis, collaborating with GSK under UNITE4TB project. Results expected by end of 2027

GSK Phase 2b BioVersys AlpE Pulmonary Tuberculosis
BRIEF

published on 03/05/2026 at 07:05, 16 days 6 hours ago

BioVersys Set to Announce 2025 Financial Results and Business Update

Financial Results Conference Call Strategic Outlook Antibacterial Products BioVersys
PRESS RELEASE

published on 03/05/2026 at 07:00, 16 days 6 hours ago

BioVersys to Report its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
BioVersys AG to report Full Year 2025 financial results, provide business update, and host conference call on March 18, 2026. Focus on antibacterial products for MDR bacteria

Financial Results BioVersys AG Antibacterial Products MDR Bacteria Full Year 2025
BRIEF

published on 03/04/2026 at 07:05, 17 days 6 hours ago

BioVersys Publishes BV100 Phase 1 Clinical Data

Clinical Trial BV100 BioVersys Pharmacokinetics Acinetobacter Baumannii
PRESS RELEASE

published on 03/04/2026 at 07:00, 17 days 6 hours ago

BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
BioVersys announces publication of BV100 Phase 1 clinical data in Journal of Antimicrobial Agents and Chemotherapy

Clinical Data Phase 1 BV100 BioVersys Antibacterial

1 2 ... 6

Published on 03/20/2026 at 23:00, 14 hours 11 minutes ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 15 hours 41 minutes ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 15 hours 56 minutes ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 23 hours 41 minutes ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 1 day ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/20/2026 at 22:45, 14 hours 26 minutes ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 16 hours 6 minutes ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 16 hours 6 minutes ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 21:00, 16 hours 11 minutes ago

BRP Unveils the Winners of its 6th International Design Challenge
Published on 03/20/2026 at 20:05, 17 hours 6 minutes ago

INVESTOR ALERT: Goeasy Ltd. Shareholder Class Action

View all EQS

Published on 03/20/2026 at 19:00, 18 hours 11 minutes ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 18 hours 56 minutes ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 17:45, 19 hours 26 minutes ago

Cie du Bois Sauvage : Annual report 2025
Published on 03/20/2026 at 16:57, 20 hours 14 minutes ago

Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 1 day 19 hours ago

Filing of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE

News